Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16270149 | 0.88 | ADORA3 (0.40) | ADORA3ADORA2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL24276762 | 0.87 | ADORA3 (0.40) | ADORA3ADORA2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL24213262 | 0.87 | DRD2 (0.41) | BRD4ALDH1A1CCNCCDK8GFER | |
| SCHEMBL27341116 | 0.85 | HPGD (0.43) | ADORA3ADORA2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL31459552 | 0.84 | GAA (0.41) | ADORA3ADORA2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL25169810 | 0.84 | FAAH (0.39) | ADORA3ADORA2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL27341129 | 0.83 | ADORA3 (0.37) | ADORA3ADORA2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL20141716 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9AMAPTALDH1A1LMNA | |
| SCHEMBL16270159 | 0.83 | ADORA3 (0.39) | ADORA3ADORA2AKDM4EMAPTBRD4 | |
| SCHEMBL18187532 | 0.82 | ALDH1A1 (0.45) | ADORA3ADORA2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240383868-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118434744-A | Nitrogen-containing macrocyclic compound, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240034723-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| EP-4294790-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-116669769-A | Piperidinyl small molecule degradants of HELIOS and methods of use | 达纳－法伯癌症研究所公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4228651-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| EP-4143180-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715287-A | Substituted N- (methyl-d 3) pyridazine-3-carboxamide or N- (methyl-d 3) -nicotinamide compounds as IL-12, IL-23 and/or IFN alpha modulators | 百时美施贵宝公司 | 2023-02-24 | — | — | CN | disclosed |
| US-9676782-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676782-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676782-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY | 2014-07-31 | — | — | US | disclosed |
| US-8703946-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2012083224-A1 | BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012078817-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | GRM3, GRM1, GRIN3A | ADORA3 131/4885ADORA2A 198/4885SMN1; SMN2 2660/4885 |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | ADORA3 290/4885ADORA2A 1378/4885SMN1; SMN2 2161/4885 |
| US-20140213593-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM3 | ADORA3 120/4885ADORA2A 133/4885SMN1; SMN2 2961/4885 |
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | TYK2, IRAK3, JAK3 | ADORA3 324/4885ADORA2A 1208/4885SMN1; SMN2 1878/4885 |
| US-20240383868-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ADORA3 3738/4885ADORA2A 3263/4885SMN1; SMN2 716/4885 |
| US-20240034723-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, NUTF2 | ADORA3 4616/4885ADORA2A 4533/4885SMN1; SMN2 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.